This is a working overview of Reverse-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-06. Anything still debated is marked as such rather than presented as settled.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | About 1419.5 Da | Calculated from the fifteen-residue sequence |
| Residue count | 15 amino acids | Single-letter sequence GEPPPGKPADDAGLV |
| Compound class | Synthetic peptide | Produced by solid-phase synthesis |
| Synonyms | BPC 157; pentadecapeptide BPC 157 | Naming varies across suppliers and papers |
| Appearance | White to off-white powder | Typical form of the lyophilized material |
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
=== Category:EC 3.3 (act on ether bonds) === Category:EC 3.3 Adenosylmethionine hydrolase S-adenosyl-L-homocysteine hydrolase Alkenylglycerophosphocholine hydrolase Alkenylglycerophosphoethanolamine hydrolase Cholesterol-5,6-oxide hydrolase Hepoxilin-epoxide hydrolase Isochorismatase Leukotriene-A4 hydrolase Limonene-1,2-epoxide hydrolase Microsomal epoxide hydrolase Trans-epoxysuccinate hydrolase
Carrasco had previously been Castillo's Interior Minister during the Bellido cabinet. On 19 November, Presidential Secretary Bruno Pacheco resigned. Pacheco claimed to be innocent, and said he was resigning to stop the smear campaign against the president.
=== Priori Development and the ERIAD Controversy === John Fenn's development of electrospray ionization was preceded by the ERIAD method, a direct analogue created by Lidija Gall's group in the Soviet Union. Gall's team recorded mass spectra of peptides and proteins as early as 1981. During a 1983 visit to the Soviet Union, Fenn visited Lidija Gall's laboratory and engaged in "fruitful discussions" regarding her ERIAD method, which he described as "very promising". Although Gall published her findings in April 1984, which was five months before Fenn's first paper on the subject, her work remained largely unknown internationally for decades due to the "Iron Curtain". Despite this direct exposure to the technology and his comment that he would "try it in his lab," Fenn's subsequent 1984 publication did not cite Gall's earlier pioneering work. Gall's pioneering contributions were later recognized by the Nobel Committee in 2002 and through her receipt of the Thomson Medal in 2022.
Furthermore, the brain has a higher density of histamine H1 receptors than any body organ examined which may account for why chlorpromazine and other phenothiazine antipsychotics are as potent at these sites as the most potent classical antihistamines. In addition to influencing the neurotransmitters dopamine, serotonin, epinephrine, norepinephrine, and acetylcholine it has been reported that antipsychotic drugs could achieve glutamatergic effects. This mechanism involves the direct effects of antipsychotic drugs on glutamate receptors. By using the technique of functional neurochemical assay chlorpromazine and phenothiazine derivatives have been shown to have inhibitory effects on NMDA receptors that appeared to be mediated by action at the Zn site. It was found that there is an increase of NMDA activity at low concentrations and suppression at high concentrations of the drug. No significant difference in glycine activity from the effects of chlorpromazine was reported. Further work will be necessary to determine if the influence in NMDA receptors by antipsychotic drugs contributes to their effectiveness. Chlorpromazine does also act as a FIASMA (functional inhibitor of acid sphingomyelinase). Chlorpromazine is an antagonist to H1 receptors (provoking antiallergic effects), H2 receptors (reduction of forming of gastric juice), M1 and M2 receptors (dry mouth, reduction in forming of gastric juice) and some 5-HT receptors (different anti-allergic/gastrointestinal actions). Because it acts on so many receptors, chlorpromazine is often referred to as a "dirty drug".
12 October Researchers report successful transplantation of human brain tissue organoids into baby rats. Such research could eventually controversially raise ethical issues relating to (non-)human intelligence/consciousness/welfare and be used to model human brain development and, as demonstrated, to investigate diseases (and their potential therapies). Unlike in other recent studies, the tissues appeared to be highly functional, to mature and to integrate with the rat brain. A study reports that in a cohort of symptomatically infected, 46% had only partially recovered after 12 months, that asymptomatic infection was not associated with adverse outcomes of long COVID and that vaccination was associated with reduced risk of seven long-term symptoms. A meta-analysis published on the same day reports substantial exercise intolerance more than 3 months after infection in long COVID-19 patients. It notes that post-exertional malaise has been reported in long COVID-19 similar to CFS. 13 October A novel synthetic biology-based process for recycling of plastics mixtures is presented. Scientists report that in some cases, some apparently senescent cells – which are targeted by anti-aging senolytics – are required for regeneration. 14 October – Scientists from Boston University publish unauthorized (but legal) research on SARS-CoV-2 BA.1 Omicron via creation of a highly transmissible recombinant virus as a preprint, described by "many" but not all as "irresponsible gain-of-function" research.
Sources: en.wikipedia.org
== Effects on cytotoxic edema == Purinergic receptors have been suggested to play a role in the treatment of cytotoxic edema and brain infarctions. It was found that with treatment of the purinergic ligand 2-methylthioladenosine 5' diphosphate (2-MeSADP), which is an agonist and has a high preference for the purinergic receptor type 1 isoform (P2Y1R), significantly contributes to the reduction of an ischemic lesions caused by cytotoxic edema. Further pharmacological evidence has suggested that 2MeSADP protection is controlled by enhanced astrocyte mitochondrial metabolism through increased inositol triphosphate-dependent calcium release. There is evidence suggesting a relationship between the levels of ATP and cytotoxic edema, where low ATP levels are associated with an increased prevalence of cytotoxic edema. It is believed that mitochondria play an essential role in the metabolism of astrocyte energy within the penumbra of ischemic lesions. By enhancing the source of ATP provided by mitochondria, there could be a similar 'protective' effect for brain injuries in general.
2024 Bushey killings: Police announce that a manhunt is underway for Kyle Clifford, a 26-year-old man suspected of murdering three women in Bushey, Hertfordshire, using a crossbow. The public is warned not to approach him. Police identify the three women as 61-year-old Carol Hunt, wife of BBC Racing commentator John Hunt, and two of their daughters, Hannah Hunt, 28 and Louise Hunt, 25. Clifford is found and arrested in Enfield by the early evening. Euro 2024: England win 2–1 against the Netherlands, with Ollie Watkins scoring a 90th minute winning goal, taking them through to the final against Spain. 11 July Data shows the UK economy grew by 0.4% in May, expanding more than had been expected. A manhunt is launched after two suitcases containing human remains are found at the Clifton Suspension Bridge in Bristol. 12 July Four migrants die and 63 are rescued after their small boat capsizes in an attempt to cross the English Channel. According to International Organization for Migration this brings the total deaths resulting from such crossing attempts to more than 20 so far for 2024. Royal Mail unveil their new logo, based on the Tudor Crown used in the royal cypher of King Charles III, which replaces the St Edward's Crown used by Queen Elizabeth II. The first post box with the new logo is in Cambourne, Cambridgeshire. Following his guilty verdict on 4 July, Gavin Plumb is sentenced to life imprisonment, with a minimum term of 15 years.
α-1-Adrenoceptor, an adrenergic receptor with the primary effect of vasoconstriction Alpha-1 blocker, a variety of drugs which block α1-adrenergic receptors in arteries and smooth muscles Adenosine A1 receptor EPH receptor A1 A1, a subfamily of rhodopsin-like receptors SR-A1, a type of scavenger receptors domains
Crick's view of the relationship between science and religion continued to play a role in his work as he made the transition from molecular biology research into theoretical neuroscience. Crick asked in 1998 "and if some of the Bible is manifestly wrong, why should any of the rest of it be accepted automatically? ... And what would be more important than to find our true place in the universe by removing one by one these unfortunate vestiges of earlier beliefs?" In 2003 he was one of 22 Nobel laureates who signed the Humanist Manifesto.
The General dumps the cargo module Archer is hiding in to gain speed and leaves the AI facility's science team behind to die. As Archer progresses through the facility, he learns that the Mainframe's primary battle is with a major Xenome infestation that the humans brought onto the moon. Fighting both attack drones and Xenomes alike, Archer makes his way through the facility. Despite the Mainframe's best efforts, Archer manages to destroy most of the "kata-space anchors" that keep the moon from falling to the planet below. Archer survives the destruction of the anchors, but is stranded on the falling moon. Archer eventually finds the Mainframe and they form an uneasy alliance: the Mainframe will provide an aerial drone for Major Archer to escape in, but only if he takes the Mainframe's core with him. Major Archer agrees, and they battle through hordes of Xenome forces with the help of the Mainframe's attack drones. Major Archer and the AI successfully reach and board the aerial drone, but fail to navigate through an asteroid field on their way into kata-space and crash land on a desert planet called Icnus, encountering and fighting rogue Gunmen. Icnus turns out to be the location of the General's main Xenome facility. Archer battles his way through the facility with the help of the Mainframe, accidentally causing a captured Worm Xenome, one of the most dangerous Xenomes in existence, to break loose. The Mainframe helps Archer to the General's location and they engage in a firefight, where the AI's newly constructed Super Drone defeats the General's Kata-Drone.
Sources: en.wikipedia.org
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.
The number is an internal laboratory designation from the research group that first described the fragment. It does not encode a molecular weight, a receptor target, or a measured biological effect, and it carries no meaning outside the naming history of the compound.
It contains fifteen amino acid residues and has a calculated mass of roughly 1419.5 daltons. That places it in the short-peptide range, well below the size of small proteins, which affects how it is synthesized, purified, and analyzed.
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.